WO2001043759A3 - Use of 11cby popypeptides and polynuceotides - Google Patents

Use of 11cby popypeptides and polynuceotides Download PDF

Info

Publication number
WO2001043759A3
WO2001043759A3 PCT/EP2000/012703 EP0012703W WO0143759A3 WO 2001043759 A3 WO2001043759 A3 WO 2001043759A3 EP 0012703 W EP0012703 W EP 0012703W WO 0143759 A3 WO0143759 A3 WO 0143759A3
Authority
WO
WIPO (PCT)
Prior art keywords
11cby
popypeptides
polynuceotides
polypeptides
neuropathies
Prior art date
Application number
PCT/EP2000/012703
Other languages
French (fr)
Other versions
WO2001043759A2 (en
Inventor
Colin A Campbell
Sarah Jane Hadingham
David Charles Harrison
Guillaume Jean Hervieu
Original Assignee
Smithkline Beecham Plc
Colin A Campbell
Sarah Jane Hadingham
David Charles Harrison
Guillaume Jean Hervieu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, Colin A Campbell, Sarah Jane Hadingham, David Charles Harrison, Guillaume Jean Hervieu filed Critical Smithkline Beecham Plc
Priority to AU31587/01A priority Critical patent/AU3158701A/en
Publication of WO2001043759A2 publication Critical patent/WO2001043759A2/en
Publication of WO2001043759A3 publication Critical patent/WO2001043759A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The use of 11CBY polypeptides and polynucleotides in the design of protocols for the treatment of stroke, pain, or neuropathies, among others, and diagnostic assays for such conditions. Also disclosed are methods for producing such polypeptides by recombinant techniques.
PCT/EP2000/012703 1999-12-16 2000-12-12 Use of 11cby popypeptides and polynuceotides WO2001043759A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU31587/01A AU3158701A (en) 1999-12-16 2000-12-12 New use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9929772.3 1999-12-16
GBGB9929772.3A GB9929772D0 (en) 1999-12-16 1999-12-16 New use

Publications (2)

Publication Number Publication Date
WO2001043759A2 WO2001043759A2 (en) 2001-06-21
WO2001043759A3 true WO2001043759A3 (en) 2002-05-30

Family

ID=10866456

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/012703 WO2001043759A2 (en) 1999-12-16 2000-12-12 Use of 11cby popypeptides and polynuceotides

Country Status (3)

Country Link
AU (1) AU3158701A (en)
GB (1) GB9929772D0 (en)
WO (1) WO2001043759A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221613B1 (en) 1998-12-31 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
US7078484B2 (en) 2001-04-19 2006-07-18 Neurogen Corporation Melanin concentrating hormone receptors
US7078187B2 (en) 2001-04-19 2006-07-18 Neurogen Corporation Melanin concentrating hormone receptors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990002551A2 (en) * 1988-09-13 1990-03-22 Biosource Genetics Corporation Prophylaxis and treatment of nervous system diseases with melanin
EP0848060A2 (en) * 1996-12-11 1998-06-17 Smithkline Beecham Corporation Novel human 11CB splice variant
WO1999028492A1 (en) * 1997-12-03 1999-06-10 Smithkline Beecham Corporation A method of finding agonist and antagonist to human 11cb splice variant
WO2000015793A2 (en) * 1998-09-17 2000-03-23 Incyte Pharmaceuticals, Inc. Human gpcr proteins
WO2000049170A1 (en) * 1999-02-18 2000-08-24 Smithkline Beecham Corporation MURINE 11cby RECEPTOR

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990002551A2 (en) * 1988-09-13 1990-03-22 Biosource Genetics Corporation Prophylaxis and treatment of nervous system diseases with melanin
EP0848060A2 (en) * 1996-12-11 1998-06-17 Smithkline Beecham Corporation Novel human 11CB splice variant
WO1999028492A1 (en) * 1997-12-03 1999-06-10 Smithkline Beecham Corporation A method of finding agonist and antagonist to human 11cb splice variant
WO2000015793A2 (en) * 1998-09-17 2000-03-23 Incyte Pharmaceuticals, Inc. Human gpcr proteins
WO2000049170A1 (en) * 1999-02-18 2000-08-24 Smithkline Beecham Corporation MURINE 11cby RECEPTOR

Also Published As

Publication number Publication date
GB9929772D0 (en) 2000-02-09
WO2001043759A2 (en) 2001-06-21
AU3158701A (en) 2001-06-25

Similar Documents

Publication Publication Date Title
WO1998031799A3 (en) Polynucleotides and polypeptides encoding receptors
ZA200205191B (en) LIV-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer.
WO1999058683A3 (en) BASB029 POLYNUCLEOTIDE(S) AND POLYPEPTIDES FROM $i(NEISSERIA MENINGITIDIS)
EP0939124A3 (en) MGBP1 sequences
WO1999035266A3 (en) Human urotensin ii
WO2001043759A3 (en) Use of 11cby popypeptides and polynuceotides
NO20000731D0 (en) Neisseria lactodweeinbindingsprotein
AU2002364808A1 (en) Polynucleotide and protein involved in synaptogenesis, variants thereof, and their therapeutic and diagnostic uses
EP0885959A3 (en) Human Wnt-5b protein
EP0887416A3 (en) Human AFC1
AU2002309646A1 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
WO2000043519A3 (en) Neisseria meningitidis polypeptides
WO2002089828A3 (en) Interferons in the treatment of ischemia
WO2001004141A3 (en) Seripancrin
EP0887415A3 (en) Human RCE1
WO2001085921A3 (en) Human serine-threonine kinase-4
GB0217548D0 (en) Four human zinc-finger-containing proteins:MDZ3.MDZ4,MDZ7 and MDZ12
WO2002034768A3 (en) Polypeptides and polynucleodides from haemophilus influenzae and their use
AU2001273224A1 (en) Isolated polynucleotides encoding human 5'-nucleotide cn-ia and cn-ib, isolated proteins encoded by the same, and methods utilizing the same
WO2003004609A3 (en) Novel human kielin-like proteins and polynucleotides encoding the same
DK1122307T3 (en) Human carnosinase 2
AU2002354963A1 (en) Tropomyosin isoforms, and diagnostic and therapeutic uses therefor
AU2002233839A1 (en) Peptide fragments, derived from human telomerase reverse transcriptase
WO2001043760A3 (en) Use of ucp3 polynucleotides and polypeptides
WO2001042435A3 (en) Novel human kinase proteins and polynucleotides encoding the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP